Vimarsana
Biggest News Aggregation in the World

Page 33 - Accessed August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed August Today - Breaking & Trending Today

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease - Vimarsana News

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved...

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Tagrisso approved in Japan for early lung cancer - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Tagrisso approved in Japan for early lung cancer

Investegate announcements from AstraZeneca PLC, Tagrisso approved in Japan for early lung cancer

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC - Vimarsana News

Accelerated Approval for Enhertu, HER2-Mutant Metastatic NSCLC

The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for previously treated adults with HER2-mutated unresectable or metastatic NSCLC.

Auvelity Approved for Major Depressive Disorder - Vimarsana News

Auvelity Approved for Major Depressive Disorder

The FDA has approved Auvelity (dextromethorphan HBr-buproprion HCl) extended-release tablets for the treatment of major depressive disorder.

Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib) - Vimarsana News

Children with Chronic Graft Versus Host Disease (cGVHD) May Now Be Prescribed IMBRUVICA® (ibrutinib)

The U.S. Food and Drug Administration approved the use of IMBRUVICA for the treatment of pediatric patients one year and older with cGVHD after failure of one...